Lung cancer risk and tumor characteristics differ between sexes. Estrogen has been suggested to counteract lung cancer development. We aimed to test the hypothesis that digitalis use decreases lung cancer risk due to its estrogenic and other anticancer properties in men. This was a nationwide Swedish population-based cohort study between July 1, 2005 and December 31, 2013. Data on the use of digitalis and organic nitrates in all male individuals were derived from the Swedish Prescribed Drug Registry. New lung cancer diagnoses among cohort participants were identified from the Swedish Cancer Registry. Cox proportional hazards regression was employed to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of lung cancer in digitalis users (exposed participants) compared to users of organic nitrates without digitalis medication (unexposed participants). The study cohort contained 74,437 digitalis users and 297,301 organic nitrates users. Long-term use (2 years) of digitalis was associated with decreased HRs of total lung cancer (HR 0.55, 95% CI 0.39-0.79) and squamous cell carcinoma (HR 0.40,. This large and population-based study suggests decreased risks of lung cancer overall and squamous cell carcinoma associated with long-term use of digitalis in men.
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The excess risk of lung cancer in men may be partly explained by sex differences in the prevalence of tobacco smoking. 2, 3 The male-to-female incidence ratio of lung cancer has been gradually approaching 1 in Scandinavian populations, which may be attributable to the increasing prevalence of smoking in women in recent years. [4] [5] [6] On the other hand, explanations from exposures other than tobacco smoking, including intrinsic exposures, on such sex difference have being suggested. Particularly, in the light of the sex difference in incidence and the discovery of estrogen receptors' expression in normal lung tissue and lung cancer cells, 7 a possible role of estrogen in the etiology of lung cancer has been suggested. Previous epidemiological studies have suggested that exogenous estrogen by means of hormone replacement therapy may prevent lung cancer in women. 8, 9 However, the role of estrogen exposure in male lung cancers has not been studied.
Digitalis is a group of commonly used medications for cardiovascular diseases, particularly congestive heart failure and atrial fibrillation. Interestingly, digitalis compounds can simulate some functions of estradiol, the principal estrogen, by binding to its receptors, 10 providing a unique opportunity to study the effects of estrogenic exposures on lung cancers development in men. In addition, digitalis also has potential anticancer properties by regulating intracellular events and manipulating gene expression. 11 To investigate whether digitalis use plays a protective role in the onset of lung cancer in men, we conducted this large and population-based cohort study.
Material and Methods

Study design
This was a nationwide Swedish population-based cohort study during the study period July 1, 2005 to December 31, 2013 . The source population of the study cohort was composed of all male residents in Sweden. The data on medication were retrieved from the Swedish Prescribed Drug Registry, which started July 1, 2005 from which date it has recorded every prescribed and dispensed medication in Sweden. 12 The study cohort included all male individuals ever having used digitalis (exposed) or organic nitrates without digitalis (unexposed) recorded in this registry during the study period. The cohort entry (start of follow-up) was the dates of the first prescription of digitalis or organic nitrates for both exposed and unexposed individuals. The Anatomical Therapeutic Chemical (ATC) classification codes "C01AA" and "C01DA" were used to define users of digitalis and organic nitrates, respectively. Excluded from the cohort were individuals who had a diagnosis of lung cancer recorded in the Swedish Cancer Register prior to their first known exposure to digitalis or organic nitrates. We also excluded organic nitrates users who also used digitalis. The final cohort members were linked to the Swedish Cancer Registry, Swedish Causes of Death Registry and the Swedish Patient Registry for individual data on cancer incidence, date of death and presence of comorbidities, respectively. These linkages were enabled by the 10-digit Swedish personal identity number, which is uniquely assigned to each Swedish resident upon birth or immigration. All cohort members were followed up until the occurrence of lung cancer, death or the end of the study (December 31, 2013), whichever occurred first. This study was approved by the Regional Ethical Review Board in Stockholm, Sweden (2015/3: 8).
Data collection
The Swedish Prescribed Drug Registry provided data on the exposure to digitalis and organic nitrates, and has nearly 100% completeness. 12 We extracted dates of prescription and dispensing, dosages and quantity of prescribed medications. The quantity was assessed by calculating the amount of dispensed packages and the number of defined daily doses (DDDs) per package. The Swedish Cancer Registry was used to identify all new occurrences of lung cancer during the follow-up of the cohort. This registry records at least 96% of all malignant cases. 13 The Swedish Patient Registry provided data on potential confounders considered in this study, i. Registry was used to censor cohort members from the date of death. This registry holds continuously and highly updated and >99% complete information on dates of death.
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Statistical analysis v 2 test was used to assess differences in the distribution of characteristics among exposed and unexposed cohort members. Cox proportional hazards regression models were employed to estimate the hazard ratios (HRs) with 95% confidence intervals (CIs) for lung cancer in digitalis users compared to organic nitrates users (reference group). Models were adjusted for age at first exposure to digitalis or organic nitrates (categorized into <50 years, 50-59, 60-69, 70-79 or 80 years), municipality of residence (coded as dummy variables) and presence of any of the pulmonary comorbidities presented above (yes or no). To evaluate possible differences in the risk of lung cancer by histological type, we performed subgroup analysis according to histological subtype of the lung cancer, i.e., squamous cell carcinoma, adenocarcinoma and small cell lung cancer. Dose-response associations were evaluated on the basis of duration of digitalis use. The narrow dose range of digitalis prohibited analyses of various doses of this medication. Because a prescription is valid only for a maximum of 12 months in Sweden, we defined cohort members with their first prescription during the first 12 months of the study period as "prevalent users," for whom information on exposure prior to the study was unclear. The remaining cohort members were regarded "incident users." As information on medications before the start date of the Swedish Prescribed Drug Registry in 1st July 2005 was not available, we could not estimate the actual duration among the "prevalent users." We calculated the known duration of medication for these "prevalent users" of digitalis, and the result showed that 31,721 (36.5%) of the "prevalent users" had known medications for <1 year, 18,067 (20.8%) for 1-2 years, and 37,082 (42.7%) for 2 years or longer. Thus, these "prevalent users" were not necessarily long-term users, but had a great heterogeneity in terms of duration of medication. Considering the uncertainty in the duration of medication among "prevalent users," we categorized them as a separate
What's new? While estrogens are thought to play a role in lung cancer, their effects remain unclear. Epidemiological studies examining estrogen and lung cancer development have centered on women, and the results have been inconclusive. Here, to better understand the role of estrogenic exposure in lung carcinogenesis, the authors assembled a large cohort of men and examined associations between lung cancer and use of digitalis, an estrogen-mimicking compound. Digitalis use for two or more years was associated with a reduced risk of lung cancer overall. The inverse association was especially strong for squamous cell carcinoma of the lung.
group in the analysis exploring duration-response associations. This strategy has also been adopted by previous studies of similar designs. [16] [17] [18] Incident users were further divided into three subgroups according to the duration of digitalis use: <1 year, 1-2 years and 2 years, which was computed by accumulative defined daily doses (DDDs) divided by 365.25 (average days in 1 year). 17 Given the medical indications for digitalis use, these patients may require frequent medical check-ups, which may result in earlier detection of lung cancer. To address such potential detection bias, we identified a comparison group using organic nitrates, and also performed sensitivity analysis by excluding exposures within a period of 6 or 12 months before a diagnosis of lung cancer.
All analyses were performed with the statistical software package SAS 9.4 for Windows (SAS Institute, Cary, NC).
Results
Study participants
Characteristics of the cohort members are shown in Table 1 and Supporting Information Table 1 . The final cohort included 74,437 male digitalis users (316,703 person-years of follow-up) and 297,301 organic nitrates only users (1,424,070 person-years). Among the digitalis users, 46.6% were incident users. The vast majority (99%) of digitalis users were prescribed digoxin. Among users of organic nitrates, 60.1% were incident users. Users of digitalis were older than organic nitrates users. Digitalis users had a higher prevalence of pulmonary comorbidities than organic nitrates users; 15.8% of short-term (<1 year) incident digitalis users had chronic obstructive pulmonary disease, while this proportion was 7.5% in organic nitrates users. These differences were smaller in long-term (2 years) incident users (14.9% in digitalis users versus 12.1% in organic nitrates users) (Supporting Information Table 1 ).
Risk of lung cancer
Any digitalis use was not associated with the over risk of lung cancer (HR 0.98, 95% CI 0.90-1.06) or each histological subtype separately (Table 2 ). Long-term (2 years) use of digitalis was associated with strongly decreased HRs for lung cancer overall (HR 0.55, 95% CI 0.39-0.79) and even more so for squamous cell carcinoma of the lung (HR 0.40, 95% CI 0.19-0.87). Long-term use of digitalis was associated with decreased HRs for adenocarcinoma of the lung (HR 0.71, 95% CI 0.43-1.19) and small cell lung cancer (HR 0.77, 95% CI 0.24-2.43), but these associations were not statistically significant. Use of digitalis for 1-2 years was also associated with decreased risks of lung cancer overall and adenocarcinoma, but these HRs were not statistically significant (Table  2) . Short-term (<1 year) digitalis users had rather an increased HR of lung cancer (HR 1.73, 95% CI 1.48-2.02).
The sensitivity analysis suggested that excluding medications within 6 or 12 months before the lung cancer diagnosis did not materially alter the observed associations between digitalis use and lung cancer risk, except for lower HRs for short-term (<1 year) users after excluding medication within 6 months (HR 1.24, 95% CI 1.01-1.51) or 12 months (HR 1.31, 95% CI 1.06-1.62) (Fig. 1) .
Discussion
This study examining digitalis use in relation to lung cancer risk suggests a strongly protective influence of long-term (2 years) use of digitalis on the risk of developing lung cancer, particularly for squamous cell carcinoma, in men.
This study has some specific strength, including the nationwide population-based cohort design with over 370,000 participants with a complete follow-up. The data on exposures, outcomes and included confounders were highly valid and complete. The cohort included an adequate number of lung cancer cases to provide robust risk estimates for the main outcomes. To counteract possible information bias and confounding from risk factors shared by lung cancer and cardiovascular diseases, we used organic nitrates users as the reference group rather than the general population. In addition, the results from the sensitivity analyses indicated no influence of detection bias. However, there are also several limitations. Residual confounding from unmeasured risk factors is a threat. However, to reduce residual confounding from tobacco smoking, we adjusted for pulmonary comorbidities that were closely related to smoking and airborne substances. Moreover, the prevalence of pulmonary comorbidities was rather higher in digitalis users than that in the reference group, indicating that the tobacco smoking rate was likely higher in digitalis users. Thus, tobacco smoking cannot explain the decreased lung cancer risk found among users of digitalis. Also, the prevalence of chronic obstructive pulmonary disease was higher in digitalis users, and the differences between digitalis users and organic nitrates users were 8.3, 6.3 and 2.8% in short-term (<1 year), medium-term (1-2 years) and long-term (2 years) users, respectively (Supporting Information Table 1 ), indicating that smoking might have contributed to the observed increased lung cancer risk in short-term digitalis users. Short-term use is also unlikely to influence lung cancer risk. Furthermore, although age was adjusted for in the analysis, unmeasured age-related factors may also confound the results. However, since digitalis users were older than organic nitrates users, it is again more likely that the protective effect of digitalis use has been underestimated in this study. The participants were likely to have modified their lifestyle, such as quitting smoking and changing dietary habits, after their diagnoses of cardiovascular diseases, which may have reduced the long-term lung cancer risk. However, such lifestyle changes were less likely to be different between users of digitalis and organic nitrates because they would have similar motivations to change lifestyle. There is even evidence indicating that the smoking cessation rate in organic nitrates outweighs that in congestive heart failure patients (mostly digitalis users), 19, 20 which does not support the possibility of confounding from smoking cessation. Another limitation is that we could not obtain information on digitalis use before the start date of this study, which may have introduced misclassification of the exposure. However, such potential misclassification is likely to be nondifferential between digitalis and organic nitrates users, which again should result in an underestimation of the effects of digitalis use. Finally, despite the large sample size, the statistical power of some of the subgroup analyses was limited.
Lung cancer is not generally regarded a sex-hormonerelated malignancy. However, this view might be changing. The discovery of estrogen receptors' expression in lung cancer parenchymal and stromal cells argues in favor of an etiologic role of estrogen, 7, 21 and the differences in tumor characteristics and prognosis between the sexes further support the estrogen hypothesis. 2, 3 Moreover, case-control studies and a meta-analysis have suggested a protective role of hormone replacement therapy in female lung cancer risk. 8, 9, 22, 23 Existing hormone use cohort studies and randomized clinical trials have had too short a follow-up period to assess the risk of lung cancer in women. [24] [25] [26] [27] Digitalis and estradiol (the principal estrogen) share a similar basic molecular structure, and digitalis can exert estradiol properties by binding and activating estrogen receptors. 10, 28 The present study provides new evidence in support of a protective role of estrogen in lung cancer development. To the best of our knowledge, the role of estrogen in lung carcinogenesis has not been studied in men previously. Taking advantage of the estrogen-mimicking property of digitalis medication, this study has highlighted a useful model for evaluating the effect of sex hormonal exposures on cancer risk in men. Although the point estimate for small cell lung cancer also showed a protective role of long-term digitalis use, the confidence interval was too wide to draw a conclusion.
Estrogen can increase lung cancer cell apoptosis, strengthen the immune system and inhibit lung cancer progression through modulating microenvironment cytokines; however, some in vitro studies have suggested that estrogen can also promote lung cancer cell proliferation. 7, 21, 29, 30 These contradictory findings regarding the role of estrogen in lung cancer carcinogenesis remain to be elucidated. In addition to its estrogenmimicking properties, digitalis has other anticancer properties. Digitalis is a Na 1 /K 1 -ATPase (also known as the Na 1 /K 1 pump) inhibitor, which decreases the intracellular K 1 and cytoplasmic pH levels, but increases the intracellular Na1 and Ca 1 concentrations. This change of intracellular electrolytes and acidification can facilitate apoptosis and prevent malignant transformation. 31, 32 Moreover, digitalis may inhibit interleukin-8 production, DNA topoisomerase II and the tumor necrosis factor-alpha/nuclear factor-jB signaling pathway, which are drivers for malignant transformation and cancer progression. 31, 33, 34 Future research should focus on obtaining a better understanding of the anticancer properties of digitalis, including but not restricted to its estrogen-mimicking effect.
An inverse association between digitalis use and lung cancer risk is biologically plausible, but remains to be confirmed in further epidemiological studies. If a protective role of digitalis in lung cancer development is established, it might pave the way for future clinical research evaluating potential chemoprevention with digitalis analogues in high-risk individuals of lung cancer, or perhaps as adjuvant therapy following conventional curatively intended lung cancer treatment to reduce the risk of tumor recurrence.
In conclusion, this large and population-based cohort study with complete and adequate length of follow-up and a sufficient number of lung cancer cases suggests that longterm (2 years) use of digitalis is associated with a substantially decreased risk of lung cancer in men. The inverse association seems to be more pronounced for squamous cell carcinoma. These findings warrant further research in further large-scale studies with refined assessment of the exposure and control for potential confounders.
